Cell Survival Advantage in Cadmium Induced Carcinogenesis

镉诱发癌变中的细胞存活优势

基本信息

项目摘要

Project Summary Exposure to cadmium (Cd) is associated with a spectrum of human pathogenesis including the prostate cancer (CaP). A clear dose-response relation between Cd-exposure and abnormal prostate serum antigen (PSA), a marker for CaP have been reported in men exposed to Cd. However, the molecular mechanism underlying the malignant cell transformation following Cd exposure is yet to be determined, while the association between Cd and CaP in both pre-clinical and clinical models are well established. The goal of this application is to investigate the underlying mechanism of how Cd causes malignant cell transformation (from normal to transformed cells) and on the development of tumorigenesis by the Cd-transformed cells (transformed cells to tumorigenesis). Our preliminary results suggest that during cellular transformation, Cd exposure induced endoplasmic reticulum (ER)-stress, which triggered the phosphorylation of stress transducers including PERK and eIF2-α resulted in the activation of ATF4 and initiate the induction of autophagy that protects Cd- damaged cells. Although, induction of autophagy markers (Atg -12 and Atg-16L, LC3B and Lamp1) were seen in Cd-treated cells, the autophagy process is incomplete, due to failure autophagosome and autolysosome fusion, which allowed the damaged cell to proliferate for transformation. A massive accumulation of p62 in Cd- treated cells, which also confirmed the defective autophagy. Silencing EGFR activation by siRNA or pharmacological inhibitors significantly inhibited the growth in transformed cells, but not in Cd-treated normal cells or Cd- transforming cells suggesting that EGFR activation plays a critical role, only after cellular transformation. Xenograft tumor tissues generated by Cd-transformed cells expressed high levels of ATF-4, EGFR, p62 and LC3B in correlation with in vitro findings. Moreover, increased expression of the proteins (ATF- 4, EGFR, p62, and LC3B) in human CaP specimen’s agreement with Gleason sum in comparison with benign prostatic hyperplasia and “normal” adjacent tissues. Based on the results we hypothesize that Chronic exposure of prostate epithelial cells to Cd causes ER-stress and subsequently defective autophagy, leading to increased survival of damaged cells that result in malignant cell transformation and in transformed cell EGFR activation play a significant role in tumorigenesis. Three specific aims are proposed: Aim-1: To demonstrate that Cd causes ER-stress which in turn induced defective autophagy during the transformation of prostate epithelial cells. Aim 2: Investigate the protective role of defective autophagy, which increases the survival of Cd-damaged cells during the transformation of prostate epithelial cells. Aim-3: study Cd-induced tumorigenesis in mouse models and validate the molecular markers in human prostate specimens.
项目概要 接触镉 (Cd) 与一系列人类发病机制有关,包括前列腺癌 (帽)。镉暴露与异常前列腺血清抗原 (PSA) 之间存在明确的剂量反应关系, 据报道,暴露于镉的男性中存在 CaP 标记物。然而,其背后的分子机制 镉暴露后的恶性细胞转化尚未确定,而镉与镉之间的关联 和 CaP 在临床前和临床模型中均已成熟。该应用程序的目标是 研究镉如何引起恶性细胞转化(从正常细胞到 转化细胞)和镉转化细胞(转化细胞)肿瘤发生的发展 细胞肿瘤发生)。我们的初步结果表明,在细胞转化过程中,镉暴露 诱导内质网(ER)应激,触发应激传感器的磷酸化,包括 PERK 和 eIF2-α 导致 ATF4 激活并启动自噬的诱导,从而保护 Cd- 受损的细胞。尽管观察到自噬标记物(Atg -12 和 Atg-16L、LC3B 和 Lamp1)的诱导 在经镉处理的细胞中,由于自噬体和自溶酶体失效,自噬过程不完整 融合,使受损细胞能够增殖进行转化。 p62 在 Cd- 中大量积累 处理的细胞,这也证实了自噬缺陷。通过 siRNA 沉默 EGFR 激活或 药物抑制剂显着抑制转化细胞的生长,但不抑制镉处理的正常细胞的生长 细胞或 Cd 转化细胞表明 EGFR 激活发挥着关键作用,只有在细胞 转变。 Cd转化细胞产生的异种移植肿瘤组织表达高水平的ATF-4, EGFR、p62 和 LC3B 与体外研究结果相关。此外,蛋白质(ATF- 4、EGFR、p62 和 LC3B)在人 CaP 标本中与良性相比与格里森总和的一致性 前列腺增生和“正常”邻近组织。根据结果​​,我们假设慢性暴露 前列腺上皮细胞对 Cd 的吸收会导致 ER 应激,并随后导致自噬缺陷,导致 受损细胞的存活导致恶性细胞转化和转化细胞 EGFR 激活 在肿瘤发生中发挥重要作用。提出了三个具体目标: 目标 1:证明 Cd 会导致 内质网应激反过来在前列腺上皮细胞转化过程中诱导有缺陷的自噬。 目标 2:研究有缺陷的自噬的保护作用,它可以提高镉损伤细胞的存活率 在前列腺上皮细胞的转化过程中。 Aim-3:在小鼠模型中研究镉诱导的肿瘤发生 并验证人类前列腺样本中的分子标记。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chendil Damodaran其他文献

Chendil Damodaran的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chendil Damodaran', 18)}}的其他基金

Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer
去势抵抗性前列腺癌新型靶向治疗药物的开发
  • 批准号:
    10634506
  • 财政年份:
    2022
  • 资助金额:
    $ 44.14万
  • 项目类别:
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer
去势抵抗性前列腺癌新型靶向治疗药物的开发
  • 批准号:
    10337860
  • 财政年份:
    2022
  • 资助金额:
    $ 44.14万
  • 项目类别:
Elucidating the molecular signaling of Cadmium Carcinogenesis
阐明镉致癌的分子信号传导
  • 批准号:
    10338822
  • 财政年份:
    2022
  • 资助金额:
    $ 44.14万
  • 项目类别:
Elucidating the molecular signaling of Cadmium Carcinogenesis
阐明镉致癌的分子信号传导
  • 批准号:
    10633057
  • 财政年份:
    2022
  • 资助金额:
    $ 44.14万
  • 项目类别:
Cell Survival Advantage in Cadmium Induced Carcinogenesis
镉诱发癌变中的细胞存活优势
  • 批准号:
    10403011
  • 财政年份:
    2021
  • 资助金额:
    $ 44.14万
  • 项目类别:
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer
靶向 AR 和 AR 变异体治疗去势抵抗性前列腺癌
  • 批准号:
    10400349
  • 财政年份:
    2021
  • 资助金额:
    $ 44.14万
  • 项目类别:
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer
靶向 AR 和 AR 变异体治疗去势抵抗性前列腺癌
  • 批准号:
    10333417
  • 财政年份:
    2021
  • 资助金额:
    $ 44.14万
  • 项目类别:
Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer
靶向 AR 和 AR 变异体治疗去势抵抗性前列腺癌
  • 批准号:
    10553652
  • 财政年份:
    2021
  • 资助金额:
    $ 44.14万
  • 项目类别:
Cell Survival Advantage in Cadmium Induced Carcinogenesis
镉诱发癌变中的细胞存活优势
  • 批准号:
    9805759
  • 财政年份:
    2019
  • 资助金额:
    $ 44.14万
  • 项目类别:
Cell Survival Advantage in Cadmium Induced Carcinogenesis
镉诱发癌变中的细胞存活优势
  • 批准号:
    9981745
  • 财政年份:
    2019
  • 资助金额:
    $ 44.14万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 44.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了